Year All202420232022202120202019201820172016201520142013201220112009 Mar 28, 2024 REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD Mar 27, 2024 REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days Mar 11, 2024 REGENXBIO to Participate in Upcoming Investor Conferences Mar 06, 2024 REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants Mar 06, 2024 REGENXBIO Announces Proposed Public Offering of Common Stock Mar 05, 2024 REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL Feb 29, 2024 REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
Mar 28, 2024 REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
Mar 06, 2024 REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
Feb 29, 2024 REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial